Active Ingredient History
Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Psoriatic (Phase 2)
Autoimmune Diseases (Phase 2)
Diabetes Mellitus, Experimental (Phase 1/Phase 2)
Diabetes Mellitus, Type 1 (Phase 3)
Glucose Intolerance (Phase 2)
Hepatitis C, Chronic (Phase 2)
Hypoglycemia (Phase 1/Phase 2)
Islets of Langerhans Transplantation (Phase 1/Phase 2)
Melanoma (Phase 1)
Psoriasis (Phase 1/Phase 2)
Transplantation, Homologous (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue